Considerations for tisagenlecleucel dosing rationale

Authors :: Constantine S. Tam
Edmund K. Waller
Karen Thudium Mueller
Gregory A. Yanik
Ulrich Jäger
Peter Borchmann
Jason Hamilton
Michael R. Bishop
André Baruchel
Mariana Cota
Joseph P. McGuirk
Rakesh Awasthi
Michael Boyer
Edward K Waldron
Samantha Jaglowski
Heather E. Stefanski
G.D. Myers
Lida Bubuteishvili-Pacaud
Susana Rives
Source :: Journal of Clinical Oncology. 36:e15056-e15056
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e15056Background: Analyses supporting a safe and efficacious dose for CAR therapies are not well defined and vary across CAR-T programs. These analyses present key considerations to support tisagen...

Subjects :: Cancer Research
medicine.medical_specialty
business.industry
030226 pharmacology & pharmacy
03 medical and health sciences
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Key (cryptography)
medicine
Dosing
Intensive care medicine
business
human activities

Tools